- Research article
- Open Access
- Open Peer Review
Myogenic progenitors contribute to open but not closed fracture repair
© Liu et al; licensee BioMed Central Ltd. 2011
- Received: 27 June 2011
- Accepted: 22 December 2011
- Published: 22 December 2011
Bone repair is dependent on the presence of osteocompetent progenitors that are able to differentiate and generate new bone. Muscle is found in close association with orthopaedic injury, however its capacity to make a cellular contribution to bone repair remains ambiguous. We hypothesized that myogenic cells of the MyoD-lineage are able to contribute to bone repair.
We employed a MyoD-Cre+:Z/AP+ conditional reporter mouse in which all cells of the MyoD-lineage are permanently labeled with a human alkaline phosphatase (hAP) reporter. We tracked the contribution of MyoD-lineage cells in mouse models of tibial bone healing.
In the absence of musculoskeletal trauma, MyoD-expressing cells are limited to skeletal muscle and the presence of reporter-positive cells in non-muscle tissues is negligible. In a closed tibial fracture model, there was no significant contribution of hAP+ cells to the healing callus. In contrast, open tibial fractures featuring periosteal stripping and muscle fenestration had up to 50% of hAP+ cells detected in the open fracture callus. At early stages of repair, many hAP+ cells exhibited a chondrocyte morphology, with lesser numbers of osteoblast-like hAP+ cells present at the later stages. Serial sections stained for hAP and type II and type I collagen showed that MyoD-lineage cells were surrounded by cartilaginous or bony matrix, suggestive of a functional role in the repair process. To exclude the prospect that osteoprogenitors spontaneously express MyoD during bone repair, we created a metaphyseal drill hole defect in the tibia. No hAP+ staining was observed in this model suggesting that the expression of MyoD is not a normal event for endogenous osteoprogenitors.
These data document for the first time that muscle cells can play a significant secondary role in bone repair and this knowledge may lead to important translational applications in orthopaedic surgery.
Please see related article: http://www.biomedcentral.com/1741-7015/9/136
- Open Fracture
- Tibial Fracture
- Bone Repair
- Myogenic Cell
- Fracture Repair
The conventional cellular understanding of the bone repair process places progenitors originating from the periosteum and the bone marrow compartment in a pivotal role. The periosteum, a cellular layer surrounding bones, has a well defined capacity for bone repair . Mesenchymal progenitors from the marrow are also highly plastic and are involved in bone homeostasis . However, there are many orthopaedic circumstances where damage to the periosteum, debridement to prevent infection, and internal fixation limit the access by these primary osteoprogenitors. High-energy traumatic fractures and open fractures have a much higher relative risk of non-union , yet many can still go on to unite. Although one possibility is that the periosteal and/or marrow tissues are able to recover sufficiently to facilitate repair, we have hypothesized that secondary progenitor cell types are likely to compensate.
We have recently reviewed a range of progenitor cell types that may have the potential to contribute to bone repair . These include cells from the adjacent soft tissues (myogenic progenitors, vascular endothelial cells, and pericytes) as well as circulating progenitors. Myogenic cells represent a strong candidate for contributing to local bone healing. In cell culture, myogenic cells are highly responsive to osteogenic growth factors and the osteogenic response of non-myogenic cells can be increased by forced expression of the myogenic factor MyoD . Muscle-derived cells cultured ex vivo and re-implanted into mice have been shown to be able to contribute to new bone formation [6, 7]. When bone repair is observed in the clinical orthopaedic setting, the bone that first forms in response to a fracture is often seen adjacent to the local muscles . Nevertheless, such data is only circumstantial and does not specifically demonstrate that myogenic cells can contribute to bone formation in an in vivo setting.
One challenge with examining the contribution of different progenitor populations in vivo is tracking their contribution to other tissues once they have ceased expressing markers that define their origin. To overcome this limitation, researchers have started to employ Cre/loxP conditional reporter systems where early lineage specification markers can drive a permanent recombination event in all downstream tissues. In this study, we have utilized a MyoD-Cre mouse line, where the majority of early myogenic progenitors can be permanently labeled. Prior reports have indicated that the presence of MyoD-lineage cells in non-muscle tissues is a rare event , and we have confirmed this experimentally (Additional File 1, Additional File 2, Additional File 3). We determined that this would be a suitable model to examine the contribution of myogenic progenitors to orthopaedic repair.
MyoD-Cre and Tie2-Cre reporter mice have been previously employed to study the contribution of endogenous myogenic and vascular progenitors in models of heterotopic bone formation . Lounev et al reported that the process of rhBMP-2 induced intramuscular bone formation featured a negligible contribution by MyoD-lineage cells, but a major (up to 50%) contribution by Tie2-lineage cells. However, prior work by Lu et al indicated a minimal contribution by Tie2-lineage cells to fracture repair , suggesting important fundamental differences between heterotopic ossification and fracture healing.
In the present study, we have performed a detailed analysis of the contribution of MyoD-lineage cells to bone repair in the mouse tibia using a number of surgical models. First, we compared closed tibial fractures where the periosteum was largely intact with an open, highly-traumatic fracture model featuring periosteal stripping and local tissue trauma. We hypothesized that the involvement of any secondary repair systems, such as from the myogenic progenitors, would be greatest when the periosteal progenitors were deficient. Next, we examined a drill hole defect model in the proximal tibial metaphysis where all adjacent muscle tissues were stripped. Histological staining for the hAP reporter was used to determine the contribution of the MyoD-lineage cells to the fracture callus or bone defect. Adjacent sections were also co-stained for bone/cartilage matrix markers to confirm the successful transdifferentiation of the once myogenic cells into the osteogenic and chondrogenic lineages.
The MyoD-Cre mouse line expresses the Cre recombinase gene under the control of the MyoD promoter . This mouse line was a gift from A/Prof David Goldhamer (University of Connecticut, Storrs, CN, United States). In the absence of Cre recombinase, the Z/AP reporter strain constitutively expresses a lacZ transgene; upon exposure to Cre, the transgene recombines to express human placental alkaline phosphatase (hAP) . This mouse line allows specific distinct between reporter and endogenous expression as hAP is heat-resistant while endogenous alkaline phosphatase is heat-labile. This mouse line was supplied by Prof. Patrick Tam (Children's Medical Research Institute, Westmead, NSW, Australia) with permission from Prof. Andras Nagy (Samuel Lunenfeld Research Institute, Toronto, Ontario, Canada), who originally published the strain. The MyoD-Cre mouse line was on a predominantly C57BL6/J background (> 5 generations backcross) and the Z/AP line was of a mixed 129/SvJ:C57BL6/J background. MyoD-Cre+:Z/AP+ mice were generated by breeding mice heterozygous for the transgenes; MyoD-Cre-:Z/AP+ littermates were used as staining controls. For developmental experiments, transgenic embryos were produced by timed mating.
Mice were housed at the Children's Hospital at Westmead (CHW) Transgenic Facility and at the Westmead Hospital Department of Animal Care. The health status of mice was routinely monitored by animal house staff and mice were given food and water ad libitum. Animal experimentation was approved by the CHW/CMRI Animal Ethics Committee (K248) and the Westmead Hospital Animal Ethics Committee (4102).
Transgenic mice were genotyped using ear or tail DNA by standard PCR method using Taq polymerase. Tissue samples were digested with Direct PCR lysis buffer (Viagen Biotech, Los Angeles, CA, United States) with added proteinase K (333 μg/ml) at 55°C for 2 hours to overnight. Proteinase K activity was terminated by heat-denaturation at 85°C for 40 min. Samples were run on a 2% TAE agarose gel with ethidium bromide and bands visualized under UV light (AlphaImager; Quantum Scientific Pty Ltd, Murarrie, QLD, Australia). The MyoD-Cre × Z/AP mice were genotyped with primers for Cre (5'-CATCGTCGGTCCGGGCTGCC-3' and 3'-CCCCCATGGCTAAGTGCCTTC-5') and hAP (5'-ATCGCTGATTTGTGTAGTCGGT-3' and 3'-CAACAGTTGCGCAGCCTGAATG-5') using standard PCR conditions. The genotyping reaction is based on the Taq DNA polymerase methodology and was prepared according to the protocol provided by the manufacturer (Roche Diagnostics, Indianapolis, IN, United States).
Midshaft tibial fractures were created manually by three-point bending with surgical stable removers, as previously reported . Anesthesia was induced by the intraperitoneal injection of ketamine (35 mg/kg) and xylazine (4.5 mg/kg). A small incision was made slightly below the knee and a 30 G needle was inserted. After the fracture was made, its position was confirmed using a digital x-ray machine (Faxitron X-ray Corp., Wheeling, IL, United States). The 30 G needle was then replaced with a 0.3 mm-diameter stainless steel insect pin to provide additional stability with bone end alignment preserved by an experienced surgeon and confirmed by x-ray. For closed fractures, no additional procedures were performed. In open fractures, the fracture site was subsequently opened and the local periosteum stripped for ~3 mm each side of the fracture site. To mimic the traumatic soft tissue injury that is often associated with open fractures, the muscles surrounding the tibial midshaft was repeatedly manually fenestrated using magnum 15 tattoo needles. Wounds were closed using suture material and Vetbond as required. Analgesia was again given by s.c. buprenorphine and mice were monitored daily for the first 3 days. Fracture repair was monitored by weekly radiography (Faxitron x-ray) and in the event where internal fixation had failed (due to pin slippage, bending or breakage) the affected mouse was culled and excluded from subsequent analysis. Mice were euthanized for 1, 2 and 3 week time points.
Tibial drill hole
A medial skin incision was made over the proximal metaphysis of the tibia and the proximal medial tibial bone surface was exposed by elevating the covering muscle flap and thorough periosteal stripping. A defect of 1 mm diameter and 1 mm depth was created in the proximal metaphysis of the right tibiae using a spherical 1 mm burr and thoroughly rinsed with sterile saline. After the defect was made, its position was confirmed by digital x-ray. Subsequently, the muscle flap was excised and the skin closed directly over the defect leaving the defect without any muscle coverage. Anesthesia and analgesia were given as described for the tibial fracture model. Mice were euthanized for hind limb harvest at day 7 after surgery for histochemical staining.
Histochemical and immunohistochemical staining
Human alkaline phosphatase (hAP) staining
Specimens were harvested and processed for cryo-preservation. Samples were initially fixed in 0.25% glutaraldehyde at 4°C overnight and then decalcified in 0.4 M EDTA for 2-3 weeks at 4°C. Samples were then prepared for cryo-preservation by overnight incubation in a 30% sucrose solution, embedded in TissueTek O.C.T. compound (ProSciTech, Kirwan, QLD, Australia) and frozen in liquid nitrogen-cooled isopentane. 5 μm sections were cut on the Leica cryostat and collected on Superfrost slides (HD Scientific). For staining, samples were fixed with 4% paraformaldehyde (PFA) in phosphate buffered saline (PBS) for 20 min at room temperature. Slides were washed in PBS and then heat inactivated at 75°C to eliminate endogenous alkaline phosphatase staining. A NBT/BCIP solution (Roche Diagnostics, Cat # 1161451001) was diluted 1:50 in NBT/BCIP buffer (0.1 M NaCl, 0.1 M Tris-HCl pH 9.4, 0.1 M MgCl2, 0.1% Tween-20) and were used to stain hAP+ cells blue, and sections were briefly counterstained with Nuclear Fast Red. Stained slides were taken through an alcohol/xylene series and mounted. Z/AP littermates were included in all staining protocols to produce controls that would stain negative for hAP.
Collagen I and II immunohistochemistry
Collagen I and II antibodies were used to detect mature bone cells and chondrocytes respectively using standard protocols. Briefly, cryosections were fixed with 4% PFA and endogenous peroxides were blocked using 0.3% H2O2 in methanol at room temperature for 10 min. Nonspecific binding of immunoglobulin was blocked by incubating slides in 2% BSA for 20 min. Sections were incubated with the primary antibodies (Collagen I, 1:200; Collagen II, 1:200) for 2 hours at room temperature. Sections were incubated with the anti-rabbit secondary antibody (1:100). All antibodies were purchased from Abcam. Antibody complexes were detected using diaminobenzidine (DAB) substrate (Vector Laboratories, Burlingame, CA, United States). All sections were counterstained with hematoxylin for 15 sec, cleared in ethanol and xylene and mounted.
Quantification and statistical analyses
Due to group numbers being less than 10, stringent non-parametric statistical tests were employed. The differences between multiple treatment groups at each time point were analyzed using a Kruskal-Wallis test, and specific groups were compared with a Mann-Whitney U test with values of P ≤ 0.05 considered statistically significant. Statistical tests were performed using SPSS Statistics version 17 (SPSS Inc., Chicago, IL, United States).
MyoD-lineage cellular contribution to muscle and non-muscle tissues
Before performing any bone repair experiments, we performed a detailed study to examine any non-specific or developmental expression of the MyoD-Cre transgene. Developmental expression was examined in E13.5, E15.0 and E19.0 MyoD-Cre+:Z/AP+ mouse embryos. In embryo sections, hAP reporter staining was restricted to the mononuclear precursors surrounding the developing skeleton (E13.5) and later as multinucleated muscle fibers (E15.0, E19.0) (Additional File 1). The developmental profile of the hAP reporter indicated a high specificity for muscle.
A range of tissues from skeletally mature mice were then stained to examine any leakage of the promoter or any significant contribution of MyoD-lineage cells to non-muscle tissues. No hAP reporter positive cells were observed in any of these tissues, including bone, bone marrow (Additional File 2), and periosteum (Additional File 3). These data indicate, under normal developmental and physiological conditions, that expression of the MyoD-Cre transgene is restricted to the developing and mature muscle. Furthermore, muscle fibers were ubiquitously stained, confirming the role of MyoD as a master regulator of muscle and indicating that a majority of myogenic cells underwent Cre-mediated recombination.
MyoD-lineage cells contribute to open but not closed fracture repair
To examine the contribution of MyoD-lineage cells in models of bone repair, both MyoD-Cre+:Z/AP+ mice and MyoD-Cre-:Z/AP+ (Z/AP+) staining control littermates underwent fracture surgery. Both the closed and the open tibial fracture models were reproducible and all animals survived the surgery. Fractures were examined over a time course of 3 weeks and X-rays illustrated that all fractures were bridged by week 3. Fracture repair is rapid in the mouse and studies were not powered to examine differences in healing rates between closed and open tibial fractures. Mice with excessive rotation (defined as 45° or more) and comminuted fractures were excluded from subsequent analysis.
In the open fracture model, the fracture site was opened surgically and the periosteum stripped from the cortical bone. The muscle surrounding the tibia was fenestrated to induce substantive soft tissue trauma. In contrast to the closed fracture model, a major contribution by MyoD-lineage cells was observed at all stages of the fracture repair process. At week 1, numerous hAP+ cells were noted in the initial mesenchymal template, particularly in the peri-cortical region (Figure 2D, enlarged in 2D'). This included cells with an elongated mesenchymal morphology (arrow heads) and rounded cells reminiscent of chondroblasts (small arrows). By 2 weeks, a soft fracture callus had formed and cells had the distinctive rounded appearance of chondrocytes. A large proportion of these cells were hAP+ both at the fractured site and throughout the fracture callus (Figure 2E). At 3 weeks, hAP+ osteoblasts were seen on the bone surface and hAP+ osteocytes were observed embedded in the immature woven bone. The reporter positive cells at week 3 were mainly present in the callus interior, and the exterior remained mainly reporter negative (Figure 2F).
No hAP staining was observed in any of the controls samples taken from mice possessing only the Z/AP transgene (Figure 2G-I). This indicates that heat inactivation of endogenous alkaline phosphatase was complete and that all enzymatic staining was specific to the MyoD- Cre and Z/AP transgenes. As an additional internal control, no hAP reporter staining was observed in any of the non-fractured bone of MyoD- Cre+:Z/AP+ mice in either the closed or open fracture models.
MyoD-lineage contribution to open fracture repair (% of hAP+ cells)
Fracture gap (F)
Peri-cortical bone (P)
Callus area (C)
53.9 ± 4.7
40.0 ± 2.0
35.9 ± 4.5
47.0 ± 4.7
21.3 ± 2.0
13.2 ± 1.3
Endogenous osteoprogenitors do not express MyoD during bone defect repair
These orthopaedic bone repair studies offer new and valuable perspectives on the capacity of MyoD-lineage cells to contribute to bone formation and fracture repair. While the conditions associated with recalcitrant fracture repair are well described on a physiological level, the specific cell types that normally contribute to these processes remain poorly defined. Many lineage tracing studies described in the literature are complicated by issues of transient reporter expression. In the current study, the Cre/loxP system was adopted to permanently label MyoD-lineage cells and effectively track their contribution to bone. Initial studies were performed using the ROSA26R reporter strain (data not shown), however false positive staining in osteoclasts emerged as a significantly confounding factor . The Z/AP reporter strain proved to be a superior system with negligible background in adult mouse bone. Expression of hAP in MyoD-lineage cells did not appear to impair or augment fracture healing based on union or callus size by x-ray.
The MyoD-Cre reporter mouse line was selected due to its apparent specificity to myogenic cells. MyoD is a specific marker of myogenic cells and is expressed in the embryonic myotome from as early as embryonic day 9.5 (E9.5) . In muscle satellite cells, MyoD expression is initiated after satellite cell activation [17–19], however recent work by Kanisicak et al., demonstrated that all satellite cell progenitors pass through a MyoD-expressing stage sometime during their developmental history . While Goldhamer et al reported rare staining in skeletal tissues including the perichondrium and several osteocytes, it is unclear whether this was due to transgene "leakiness" or due to a rare early developmental transdifferentiation event involving the MyoD-lineage . Nevertheless, our staining in embryonic and adult tissues found transgene expression to be highly restricted to the muscle (Additional Files 1 and 2) and not in the periosteum of adult mice (Additional File 3).
Muscle flaps are often used in orthopaedic surgery and the beneficial effects of muscle proximity to fracture healing are often attributed to the high vascularity of this tissue. In contrast, we have hypothesized that in fracture repair muscle may make a direct cellular contribution to bone, acting as a "secondary periosteum" in instances where the periosteum itself is damaged or absent . To test this, we utilized two fracture models: a closed fracture model where the periosteum was largely intact and an open fracture where the bone was denuded of the periosteum with the adjacent muscle damaged.
Consistent with our hypothesis, MyoD-lineage cells made substantial contributions to every stage of the open fracture repair cascade. The greatest number of hAP+ cells in the fractured bones were located in areas closest to the initial site of impact (i.e., at the fracture gap > peri-cortical bone > external callus area) (Table 1). This could suggest that MyoD-lineage cells are one of the first cell types to migrate to the site of injury due to their close proximity to the fractured bone. The concomitant muscle trauma may facilitate the passage of MyoD-lineage cells through injured fascial compartments to the fracture site. The proportion of reporter positive cells in open fractures were found to decrease with time, suggesting that myogenic progenitors can act in the initial bone healing response, but are less involved with subsequent bone remodeling. A model by Harry et al. has demonstrated functional benefits for access to the adjacent muscle during mouse tibial fracture healing. When muscle access was physically excluded using a polymer sheath, this strongly reduced fracture healing despite adequate or increased vascularity over exclusion of fasciocutaneous tissue [21, 22].
In contrast to the traumatic open fracture scenario, MyoD-lineage cells made an insignificant contribution to closed fracture repair. This may suggest that an intact periosteum can act as a physical barrier to prevent the invasion of myogenic progenitors, and also strengthens the concept that periosteal cells contributing to repair do not transiently express MyoD. The periosteum is a highly osteogenic tissue and, when present, its contribution to bone healing is sufficient and does not require alternative osteoprogenitor sources. The lack of hAP+ cells in closed fractures also argues against the possibility of spontaneous expression of the MyoD- Cre transgene by nascent osteoprogenitor populations responsible for repair (including periosteal cells, Additional File 3). To further examine whether MyoD-lineage cells could migrate into and contribute to bone healing, we tested a tibial defect model where the adjacent musculature had been stripped. No hAP+ staining cells were observed in the healing defect supporting the hypothesis that muscle accessibility is important for the contribution of MyoD-lineage cells.
In summary, these studies show for the first time that a population or sub-population of myogenic progenitors of the MyoD-lineage can make a significant cellular contribution to bone repair. In a fracture repair setting, this required disruption of the periosteum and trauma to the local tissues. In a defect repair setting, this required direct access to the muscle. These data suggest that the recruitment of MyoD-lineage cells can be highly dependent on the nature and location of the bone injury. Even in the surgical mouse models with the greatest myogenic progenitor contribution, approximately half of the cells originated from non-myogenic lineages. Thus cell lineages other than myogenic cells including vascular cells are also likely to have a major role in bone formation and repair .
Apart from scientific clarification of the cellular contribution to bone repair in other orthopaedic models, future studies can aim to manipulate the surgical systems with the aim of maximizing MyoD-lineage cell access and mobilization to augment repair. Methods which optimize the contribution of secondary (non-periosteal) osteoprogenitors may be translatable to clinical practice and play a future role in improving the union rates of high energy and open fractures.
Acknowledgements and Funding
We would like to thank A/Prof. David Goldhamer for his gift of the MyoD-Cre mouse line, Prof. Andras Nagy for permission to use the Z/AP double reporter line and Prof. Patrick Tam for providing the line. This work was supported by grants from the Australian Orthopaedic Research Foundation (AORF) and from the National Health & Medical Research Council (NH&MRC, grant #457245). Renjing Liu was supported by a Peter Bega scholarship and Aaron Schindeler was supported by a CTF Young Investigator Award.
- Malizos KN, Papatheodorou LK: The healing potential of the periosteum: Molecular aspects. Injury. 2005, 36: S13-S19.View ArticlePubMedGoogle Scholar
- Baksh D, Song L, Tuan RS: Adult mesenchymal stem cells: characterization, differentiation, and application in cell and gene therapy. Journal of Celluar and Molecular Medicine. 2004, 8: 301-16. 10.1111/j.1582-4934.2004.tb00320.x.View ArticleGoogle Scholar
- Karladani AH, Granhed H, Kärrholm J, Styf J: The influence of fracture etiology and type on fracture healing: a review of 104 consecutive tibial shaft fractures. Archives of Orthopaedic Trauma and Surgery. 2001, 121: 325-8. 10.1007/s004020000252.View ArticleGoogle Scholar
- Schindeler A, Liu R, Little DG: The contribution of different cell lineages to bone repair: Exploring a role for muscle stem cells. Differentiation. 2009, 77: 12-8. 10.1016/j.diff.2008.09.007.View ArticlePubMedGoogle Scholar
- Liu R, Ginn SL, Lek M, North KN, Alexander IE, Little DG, Schindeler A: Myoblast sensitivity and fibroblast insensitivity to osteogenic conversion by BMP-2 correlates with the expression of Bmpr-1a. BMC Musculoskeletal Disorders. 2009, 10: 51-62. 10.1186/1471-2474-10-51.View ArticlePubMedPubMed CentralGoogle Scholar
- Young BH, Peng H, Huard J: Muscle-based gene therapy and tissue engineering to improve bone healing. Clinical Orthopaedics & Related Research. 2002, 403: S243-S251.View ArticleGoogle Scholar
- Bosch P, Musgrave DS, Lee JY, Cummins J, Shuler T, Ghivizzani TC, Evans T, Robbins TD, Huard J: Osteoprogenitor cells within skeletal muscle. Journal of Orthopaedic Research. 2000, 18: 933-44. 10.1002/jor.1100180613.View ArticlePubMedGoogle Scholar
- Stein H, Perren SM, Cordey J, Kenwright J, Mosheiff R, Francis MJ: The muscle bed--a crucial factor for fracture healing: a physiological concept. Orthopedics. 2002, 25: 1379-83.PubMedGoogle Scholar
- Chen JC, Mortimer J, Marley J, Goldhamer DJ: MyoD-cre transgenic mice: a model for conditional mutagenesis and lineage tracing of skeletal muscle. Genesis: the Journal of Genetics & Development. 2005, 41: 116-21. 10.1002/gene.20104.View ArticleGoogle Scholar
- Lounev VY, Ramachandran R, Wosczyna MN, Yamamoto M, Maidment AD, Shore EM, Glaser DL, Goldhamer DJ, Kaplan FS: Identification of progenitor cells that contribute to heterotopic skeletogenesis. Journal of Bone & Joint Surgery - American Volume. 2009, 91-A: 652-63.View ArticleGoogle Scholar
- Lu C, Marcucio RS, Miclau T: Assessing angiogenesis during fracture healing. Iowa Orthopaedic Journal. 2006, 26: 17-26.PubMedPubMed CentralGoogle Scholar
- Kanisicak O, Mendez JJ, Yamamoto S, Yamamoto M, Goldhamer DJ: Progenitors of skeletal muscle satellite cells express the muscle determination gene, MyoD. Developmental Biology. 2009, 332: 131-41. 10.1016/j.ydbio.2009.05.554.View ArticlePubMedPubMed CentralGoogle Scholar
- Lobe CG, Koop KE, Kreppner W, Lomeli H, Gertsenstein M, Nagy A: Z/AP, a double reporter for Cre-mediated recombination. Developmental. 1999, 208: 281-92.Google Scholar
- Schindeler A, Morse A, Harry LE, Godfrey CB, Mikulec K, McDonald MM, Gasser JA, Little DG: Models of tibial fracture healing in normal and Nf1-deficient mice. Journal of Orthopaedic Research. 2008, 26: 1053-60. 10.1002/jor.20628.View ArticlePubMedGoogle Scholar
- Odgren PR, MacKay CA, Mason-Savas A, Yang M, Mailhot G, Birnbaum MJ: False-positive beta-galactosidase staining in osteoclasts by endogenous enzyme: studies in neonatal and month-old wild-type mice. Connective Tissue Research. 2006, 47: 229-34. 10.1080/03008200600860086.View ArticlePubMedGoogle Scholar
- Sassoon D, Lyons G, Wright W, Lin V, Lassar A, Weintraub H, Buckingham ME: Expression of two myogenic regulatory factors: myogenin and MyoD1 during mouse embryogenesis. Nature. 1989, 341: 303-7. 10.1038/341303a0.View ArticlePubMedGoogle Scholar
- Smith CK, Janney MJ, Allen RE: Temporal expression of myogenic regulatory genes during activation, proliferation, and differentiation of rat skeletal muscle satellite cells. Journal of Cellular Physiology. 1994, 159: 379-85. 10.1002/jcp.1041590222.View ArticlePubMedGoogle Scholar
- Cooper RN, Tajbakhsh S, Mouly V, Cossu G, Buckingham ME, Butler-Browne GS: In vivo satellite cell activation via Myf5 and MyoD in regenerating mouse skeletal muscle. Journal of Cell Science. 1999, 112: 2895-901.PubMedGoogle Scholar
- Fuchtbauer EM, Westphal H: MyoD and myogenin are coexpressed in regenerating skeletal muscle of the mouse. Developmental Dynamics. 1992, 193: 34-9. 10.1002/aja.1001930106.View ArticlePubMedGoogle Scholar
- Kanisicak O, Mendez JJ, Yamamoto S, Yamamoto M, Goldhamer DJ: Progenitors of skeletal muscle satellite cells express the muscle determination gene, MyoD. Developmental Biology. 2009, 332: 131-41. 10.1016/j.ydbio.2009.05.554.View ArticlePubMedPubMed CentralGoogle Scholar
- Harry LE, Sandison A, Paleolog EM, Hansen U, Nanchahal J: Comparison of the healing of open tibial fractures covered with either muscle or fasciocutaneous tissue in a murine model. Journal of Orthopaedic Research. 2008, 26: 1238-44. 10.1002/jor.20649.View ArticlePubMedGoogle Scholar
- Harry LE, Sandison A, Pearse MF, Paleolog EM, Nanchahal J: Comparision of the vascularity of fasciocutaneous tissue and muscle for coverage of open tibial fractures. Plastic & Reconstructive Surgery. 2009, 124: 1211-9. 10.1097/PRS.0b013e3181b5a308.View ArticleGoogle Scholar
- Medici D, Shore EM, Lounev VY, Kaplan FS, Kalluri R, Olsen BR: Conversion of vascular endothelial cells into multipotent stem-like cells. Nature Medicine. 2010, 16: 1400-6. 10.1038/nm.2252.View ArticlePubMedPubMed CentralGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2474/12/288/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.